Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
Date:1/11/2011

NOVATO, Calif., Jan. 11, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of genetically-defined cancers.  

"PARP inihibtors have been validated to show survival benefits in cancer patients with tumors that have defects in DNA repair or in combination with DNA damaging agents, and BMN 673 appears to have superior potency, selectivity, and bioavailability as compared to other products in development," said Hank Fuchs, Chief Medical Officer of BioMarin.  "There are many possible targets for PARP inhibitors, and we hope to identify which cancers are more susceptible to treatment with BMN 673 in the Phase 1/2 trial.  We remain intently focused on developing our R&D pipeline and look forward to many clinical milestones in the coming year."

The Phase 1/2 trial is an open-label study of once daily, orally administered BMN 673 in approximately 70 patients ages 18 and older with advanced or recurrent solid tumors.  The primary objective of the study is to establish the maximum tolerated dose of daily oral BMN 673.  The secondary objectives are to assess the safety, tolerability, preliminary efficacy and phatrmacodynamic activity of BMN 673, and to determine the pharmacokinetic profile and recommended Phase 2 dose.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a produ
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
2. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
3. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
4. BioMarin Announces Third Quarter 2010 Financial Results
5. BioMarin to Host a Research and Development Day on October 19th
6. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
9. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
10. BioMarin Acquires ZyStor Therapeutics, Inc.
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors International ... SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer ... financial results for its first fiscal quarter ended ... Quarter Highlights and Recent Developments: ... improving its cost structure, driven by lower operating ...
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
(Date:8/3/2015)...  Array BioPharma Inc. (NASDAQ: ARRY ) ... full year of its fiscal year ended June ... of Array, noted, "Binimetinib and encorafenib, two innovative ... for regulatory submissions in 2016. Additional data shared ... colorectal cancer further validate the value of these ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... Heavy babies have more birth complications; they are also ... PORTLAND, Ore., Oct. 31 A study by ... 40,000 women and their,babies found that women who gained ... as likely to have a heavy baby. Published in,the ...
... Bulletin Board: VRML) announced today that it has ... Agreement between the parties,through October, 2009. This extension ... development and commercialization of two tests, OVA1(TM) and,VASCLIR(TM)., ... women with ovarian tumors that,are at high risk ...
Cached Medicine Technology:Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby 2Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 2Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 3Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc. 4
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest healthcare ... lab testing and precision medicine solutions that can help pharmacists and other healthcare ... than 8.6 million adverse drug events are reported in the U.S. Pharmacogenetic ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... the largest online retailer of nutritional supplements, has officially opened the polls ... 11 awards in the following categories:, ,     Brand of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Over 400 personnel of the Central Reserve Police Force (CRPF), ... to drugs and alcohol// , according to an internal survey. ... number of men who have become drug dependent and found ... ,He said the survey was started in February ...
... There appears to be no conclusive proof that ... researchers from the American Cancer Society//. This is ... ,Though many medical specialists still prescribe vitamins ... Jacobs, senior epidemiologist and vitamin specialist with the ...
... There is no need for a malaria hospital in Kolkata ... L Joshi, Director of National Vector Born Disease Control Programme. ... dengue and malaria, Joshi said last year in Kolkata only ... the corresponing year was 73., ,Reprentatives of UP, Bihar, ...
... patients who would have to fork out much less ... Merck and Pfizer losing// their patent on drugs commanding ... Ranbaxy and Dr Reddy's Laboratories are being touted as ... vacuum created by the patent expiry of two biggest ...
... for Genetic Engineering and Biotechnology (CIGB) has registered the ... production of an anti-hepatitis B vaccine. // ... a true world scientific breakthrough, and it was obtained ... process required for it. , ,At a press ...
... new study, men with prostate cancer are more influenced ... //from trusting on clinical trial evidences. ... and comparing the anecdotal experiences of others with prostate ... treatment options were entirely different from them are the ...
Cached Medicine News:Health News:Misconception on Treatment Options among Prostate Cancer Patients 2
Ideal for breast compression and contouring breast cups....
Ideal for breast compression with adjustable hook and eye closure....
Female Mini-VEST, Front Closure, X-Firm...
Male Support Brief...
Medicine Products: